Elena Nikiphorou1, Sam Norton2, Lewis Carpenter3, Josh Dixey4, David Andrew Walsh5, Patrick Kiely6, Adam Young7. 1. Whittington Hospital NHS Trust, London, UK, and Early Rheumatoid Arthritis Study, St. Albans City Hospital, St. Albans, UK. 2. Institute of Psychiatry, Psychology and Neuroscience, and Faculty of Life and Medical Science, King's College London, London, UK. 3. Centre for Lifespan and Chronic Illness Research, University of Hertfordshire, Hatfield, UK. 4. New Cross Hospital, Wolverhampton, UK. 5. Arthritis UK Pain Centre, University of Nottingham, Nottingham, UK. 6. St. Georges University Hospitals NHS Foundation Trust, London, UK. 7. Early Rheumatoid Arthritis Study, St. Albans City Hospital, St. Albans, UK.
Abstract
OBJECTIVE: To examine secular trends in demographics, clinical manifestations, and comorbidity on first presentation of rheumatoid arthritis (RA) prior to disease-modifying antirheumatic drug treatment. METHODS: A total of 2,701 patients were recruited over 25 years to 2 UK-based RA inception cohorts: the Early Rheumatoid Arthritis Study (9 centers; 1986-2001) and the Early Rheumatoid Arthritis Network (23 centers; 2002-2012). Trends in demographic and baseline clinical/laboratory and radiographic variables and comorbidities were estimated using mixed-effects models, including random effects for recruitment center. RESULTS: Age at onset increased from 53.2 to 57.7 years in 1990 and 2010, respectively (2.6 months/year; 95% confidence interval [95% CI] 1.2, 4.1). Sex ratio, the proportion living in deprived areas, and smoking status were unchanged (P > 0.05) and there were no changes in the proportion seropositive or erosive at baseline (P > 0.05). After controlling for treatment at the time of assessment, erythrocyte sedimentation rate decreased and hemoglobin increased over time (P > 0.05); however, the Health Assessment Questionnaire (HAQ), the Disease Activity Score (DAS), the DAS in 28 joints, and joint counts were unchanged (P > 0.05). The overall prevalence of comorbidity increased from 29.0% in 1990 to 50.7% in 2010, mainly due to cardiovascular and non-cardiac vascular conditions, including hypertension. There was a significant increase in body mass index (0.15 units/year; 95% CI 0.11, 0.18), resulting in an increase in the prevalence of obesity from 13.3% in 1990 to 33.6% in 2010. CONCLUSION: Age at onset and comorbidity burden, especially obesity, have increased at RA presentation over 25 years, reflecting wider demographic trends at the population level. In contrast, there were no accompanying changes in disease severity assessed by composite markers of disease activity, radiographic erosions, seropositivity, or HAQ at presentation. Treatment strategies in early RA should take greater account of the impact of comorbidity on outcomes.
OBJECTIVE: To examine secular trends in demographics, clinical manifestations, and comorbidity on first presentation of rheumatoid arthritis (RA) prior to disease-modifying antirheumatic drug treatment. METHODS: A total of 2,701 patients were recruited over 25 years to 2 UK-based RA inception cohorts: the Early Rheumatoid Arthritis Study (9 centers; 1986-2001) and the Early Rheumatoid Arthritis Network (23 centers; 2002-2012). Trends in demographic and baseline clinical/laboratory and radiographic variables and comorbidities were estimated using mixed-effects models, including random effects for recruitment center. RESULTS: Age at onset increased from 53.2 to 57.7 years in 1990 and 2010, respectively (2.6 months/year; 95% confidence interval [95% CI] 1.2, 4.1). Sex ratio, the proportion living in deprived areas, and smoking status were unchanged (P > 0.05) and there were no changes in the proportion seropositive or erosive at baseline (P > 0.05). After controlling for treatment at the time of assessment, erythrocyte sedimentation rate decreased and hemoglobin increased over time (P > 0.05); however, the Health Assessment Questionnaire (HAQ), the Disease Activity Score (DAS), the DAS in 28 joints, and joint counts were unchanged (P > 0.05). The overall prevalence of comorbidity increased from 29.0% in 1990 to 50.7% in 2010, mainly due to cardiovascular and non-cardiac vascular conditions, including hypertension. There was a significant increase in body mass index (0.15 units/year; 95% CI 0.11, 0.18), resulting in an increase in the prevalence of obesity from 13.3% in 1990 to 33.6% in 2010. CONCLUSION: Age at onset and comorbidity burden, especially obesity, have increased at RA presentation over 25 years, reflecting wider demographic trends at the population level. In contrast, there were no accompanying changes in disease severity assessed by composite markers of disease activity, radiographic erosions, seropositivity, or HAQ at presentation. Treatment strategies in early RA should take greater account of the impact of comorbidity on outcomes.
Authors: Elena Myasoedova; John M Davis; Vanessa L Kronzer; Rachel E Giblon; Elizabeth J Atkinson; Nathan K LeBrasseur; Cynthia S Crowson Journal: Semin Arthritis Rheum Date: 2021-12-31 Impact factor: 5.431
Authors: Elena Myasoedova; John M Davis; Sara J Achenbach; Eric L Matteson; Cynthia S Crowson Journal: Mayo Clin Proc Date: 2019-05-01 Impact factor: 7.616
Authors: Elena Myasoedova; John M Davis; Eric L Matteson; Sara J Achenbach; Soko Setoguchi; Shannon M Dunlay; Veronique L Roger; Sherine E Gabriel; Cynthia S Crowson Journal: Semin Arthritis Rheum Date: 2019-07-15 Impact factor: 5.532
Authors: Veerle Stouten; Sofia Pazmino; P Verschueren; Pavlos Mamouris; René Westhovens; Kurt de Vlam; Delphine Bertrand; Kristien Van der Elst; Bert Vaes; Diederik De Cock Journal: RMD Open Date: 2021-06
Authors: Daniel F McWilliams; Eamonn Ferguson; Adam Young; Patrick D W Kiely; David A Walsh Journal: Arthritis Res Ther Date: 2016-12-13 Impact factor: 5.156